Blood Transfusions and Non-Hodgkin’s Lymphoma

• Eric J. Chow ^[1] ; Elizabeth A. Holly ^[2]
  1. [1] University of California School of Medicine, San Francisco, CA
  2. [2] Department of Epidemiology and Biostatistics, University of California School of Medicine, San Francisco, CA
• Localización: Epidemiologic reviews, ISSN 0193-936X, ISSN-e 1478-6729, Vol 24, 2, 2002, págs. 269-279
• Idioma: inglés
• Enlaces
  • Texto Completo Ejemplar
• Resumen

  • Non-Hodgkin’s lymphoma is the fifth most frequently diagnosed cancer in the United States, with 53,900 new cases expected in 2002 (1). The incidence of non-Hodgkin’s lymphoma in the United States and western Europe has risen by at least 100 percent over the past five decades, with annual increases in incidence averaging 3–4 percent since the 1970s (2, 3). According to the Surveillance, Epidemiology, and End Results (SEER) cancer registry, the age-adjusted annual incidence rate from 1990 to 1997 in the United States was 15.5 per 100,000 population (4). This increase has involved all adult age groups, both sexes, and most geographic areas (2, 3, 5). Overall, incidence rates increase with age, are higher in men than in women, and are higher in Caucasians than in persons of other races/ethnicities (6). However, while incidence rates among Caucasians increased more slowly during the 1990s, they are still increasing rapidly among Blacks (6). In contrast, incidence rates of other immune system cancers such as Hodgkin’s disease, multiple myeloma, and lymphocytic leukemia have remained stable over the past 30 years (2, 3). Increases in non-Hodgkin’s lymphoma have also been seen globally. Overall, rates appear to be lowest in Asian nations and intermediate in Latin America as compared with the higher rates seen in western industrialized nations (7).